Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aon PLC (AON) vs Biogen Inc (BIIB) Price & Performance

Biogen IncTrade

Price performance (Past 24H)

Key statistics

Aon PLC vs Biogen Inc — how do they compare? Aon PLC trades at $352.22 (market cap $75.61B), while Biogen Inc trades at $207.38 (market cap $30.13B). The key difference: Aon PLC is far larger — about 2.5× Biogen Inc's market cap, and Aon PLC pays a 0.92% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

AONBIIB
Market Cap
$75.61B$30.13B
Sector
FinancialsHealth
52-Week High
$381.26$216.63
52-Week Low
$308.22$128.93
Enterprise Value
$90.22B$37.20B
Dividend Yield
0.92%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aon PLC

AON trades at $356.97, down 0.37% with neutral technical signals. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $3.81 versus $3.80 expected, marking the third consecutive quarterly beat. Revenue growth accelerated to 5% organic in Q2 2026, while margins expanded 70 basis points. Analyst consensus price target stands at $410, representing 15% upside potential from current levels.

AON presents a compelling investment case with consistent earnings outperformance and robust profitability metrics including 44.88% ROE. However, premium valuation multiples and modest organic growth create headwinds. The stock offers 15% upside to consensus targets but requires monitoring of valuation compression risks amid competitive insurance brokerage markets.

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aon PLC

Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.

Read more on AON

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB